Biogen’s tau therapy drives bigger benefits in 2-year Alzheimer’s update

Biogen
Biogen linked its 60-mg, twice-yearly diranersen regimen to a 38% slowing of clinical decline. (Photo by John Tlumacki/The Boston Globe via Getty Images)

Biogen has linked its tau-targeting antisense oligonucleotide to a further slowing of clinical decline after two years, leading analysts to hail the strengthening of evidence supporting late-phase development.

The phase 2 Celia trial delivered mixed data in May, with a miss on the primary dose-response endpoint offsetting reductions in tau pathology and cognitive benefits. Biogen built out the case for the therapy, diranersen, at an event in July and arrived at this week’s Clinical Trials on Alzheimer’s Disease (CTAD) 2026 conference with data from the study’s ongoing open-label extension stage.

At Week 96, Biogen linked its 60-mg, twice-yearly diranersen regimen to a 38% slowing of clinical decline, as assessed using the Clinical Dementia Rating–Sum of Boxes (CDR-SB). Biogen reported a 26% slowing of clinical decline on CDR-SB at Week 76. 

The 38% slowing of decline corresponded to a 1.09-point treatment difference. A 1-point difference on CDR-SB is generally considered highly meaningful by clinicians, Biogen said. Eli Lilly reported (PDF) a 0.7-point treatment difference at Week 76 of a phase 3 Kisunla trial. Biogen and Eisai’s Leqembi achieved (PDF) a 0.45-point difference at Month 18 of a pivotal study.

Diranersen’s effect on CDR-SB appears clinically meaningful, BMO Capital Markets analysts said in a note to investors. However, the analysts cautioned that Biogen’s comparison of the original diranersen cohort to patients initially assigned to placebo is “imperfect.” At Week 96, some patients in the control arm had received a dose of diranersen.

The analysts named the ongoing failure to achieve a statistically significant functional improvement as another weakness of the data. Even so, they concluded that the data support the potential of the 60-mg, twice-yearly regimen to drive “sufficient tau lowering for clinical benefit in a properly powered study.” The concordance of cognitive and functional endpoints is encouraging, the analysts added. 

Safety and tolerability concerns center on confusional states, which affected 14.8% of patients in the 60-mg, twice-yearly cohort, up from 13.1% in the cut of the data that Biogen shared in July. Biogen reported higher rates of confusional states in the medium- and high-dose cohorts, which also counterintuitively had weaker efficacy than the 60-mg, twice-yearly arm. 

BMO analysts noted the persistence of confusional states but flagged the lack of amyloid-related imaging abnormalities and less frequent dosing as areas where diranersen might have an advantage over existing beta-amyloid therapies. 

As well as supporting continued development of diranersen, the dataset offers encouragement for other companies working on anti-tau therapies. The pipeline includes Arrowhead Pharmaceuticals’ ARO-MAPT, Novartis’ NIO752 and Voyager Therapeutics’ VY7523, each of which was discussed (PDF) at CTAD.